ASX:NEUPharmaceuticals
Neuren Pharmaceuticals (ASX:NEU) Is Down 15.2% After 2025 Earnings Undershoot Expectations Has The Bull Case Changed?
Neuren Pharmaceuticals Limited has reported its full-year 2025 results, with revenue of A$84.84 million and net income of A$30.44 million, both materially lower than the prior year’s levels.
The sharp reduction in basic earnings per share from continuing operations, from A$1.1117 to A$0.2373, highlights how recent financial performance contrasts with earlier analyst expectations for the business.
We’ll now examine how this sharp drop in annual revenue and earnings shapes Neuren...